Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.

Background: The U.S. is facing an opioid epidemic, but despite mandates for pharmacotherapy for opioid use disorder to be available at Veterans Health Administration (VHA) facilities, the majority of veterans with opioid use disorder do not receive these medications. In implementation research, faci...

Full description

Bibliographic Details
Published in:Journal of Substance Abuse Treatment Vol. 95; pp. 43 - 48
Main Authors: Finlay, Andrea K., Binswanger, Ingrid A., Timko, Christine, Smelson, David, Stimmel, Matthew A., Yu, Mengfei, Bowe, Tom, Harris, Alex H.S.
Format: research Journal Article
Published: Pergamon Press - An Imprint of Elsevier Science Dec2018
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132512066&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 132512066
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        07405472
        JUB
      jtl: Journal of Substance Abuse Treatment
      issn: 07405472
      maglogo: N
    pubinfo:
      dt: Dec2018
      vid: 95
      pid: 2410
      pub: Pergamon Press - An Imprint of Elsevier Science
    artinfo:
      ui:
        132512066
        132512066
        NLM30352669
        132512066
        10.1016/j.jsat.2018.09.006
        NLM30352669
        132512066
      ppf: 43
      ppct: 5
      formats:
      tig:
        atl: Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.
      aug:
        au:
          Finlay, Andrea K.
          Binswanger, Ingrid A.
          Timko, Christine
          Smelson, David
          Stimmel, Matthew A.
          Yu, Mengfei
          Bowe, Tom
          Harris, Alex H.S.
        affil: Center for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road (152-MPD), Menlo Park, CA 94025, USA
      sug:
        subj:
          Hospitals, Veterans Standards
          Clinical Indicators
          Substance Use Disorders Drug Therapy
          United States Department of Veterans Affairs
          Veterans
          United States
          Quality Improvement
          Buprenorphine Administration and Dosage
          Naltrexone Administration and Dosage
          Methadone Administration and Dosage
          Human
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Ferrans and Powers Quality of Life Index
          Impact of Events Scale
      ab: Background: The U.S. is facing an opioid epidemic, but despite mandates for pharmacotherapy for opioid use disorder to be available at Veterans Health Administration (VHA) facilities, the majority of veterans with opioid use disorder do not receive these medications. In implementation research, facilities are often targeted for qualitative inquiry or quality improvement efforts based on quality measure performance during a one-year period. However, sites that experience quality performance changes from one year to the next may be highly informative because mechanisms that impact facility change may be more discoverable. The current study examined changes in receipt of pharmacotherapy for opioid use disorder in a national healthcare system to determine the extent to which sites fluctuated in performance over a two-year period and illustrate how changes in quality measures over time may be useful for implementation research and healthcare surveillance of quality measures.Methods: Using national VHA data from Fiscal Years (FY) 2016 and 2017, we calculated quality measure performance as the number of patients who received pharmacotherapy for opioid use disorder (i.e., methadone, buprenorphine, and naltrexone) divided by the number of patients with a current non-remitted opioid use disorder diagnosis for each FY at each facility (n = 129) and examined change from FY16 to FY17.Results: The mean rate of receipt of pharmacotherapy for opioid use disorder was 38% (facility range = 3% to 74%) in FY16 and 41% (facility range = 2% to 76%) in FY17. The average facility-level change in performance was 3% and ranged from -19% to 26%. There were 32 facilities that decreased in provision of pharmacotherapy, 12 facilities with no change, and 85 facilities that increased.Conclusions: For facilities with average or high performance, it was difficult to maintain their performance over time. Identifying and learning from facilities with recent fluctuations may be more informative to guide the design of future quality improvement efforts than studying facilities with stable high or low performance.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N